Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

18.34
+0.02000.11%
Post-market: 18.410.0700+0.38%19:56 EDT
Volume:754.59K
Turnover:13.87M
Market Cap:1.31B
PE:-5.20
High:18.69
Open:18.22
Low:18.07
Close:18.32
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.93
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5300
EPS(LYR):-3.5300
ROE:-60.78%
ROA:-33.92%
PB:4.30
PE(LYR):-5.20

Loading ...

MoonLake Immunotherap Raised to Buy From Neutral by BTIG

Dow Jones
·
Jan 09

MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating

TIPRANKS
·
Jan 09

BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap

Reuters
·
Jan 09

MoonLake Immunotherapeutics Up Nearly 26%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk

Dow Jones
·
Jan 09

MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating

TIPRANKS
·
Jan 08

MoonLake Immunotherapeutics Shares Soar 32..9% as US FDA Clears Path for Skin Disease Drug Filing

THOMSON REUTERS
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike

Reuters
·
Jan 08

Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA

Reuters
·
Jan 08

BUZZ-MoonLake soars as FDA clears path for skin disease drug filing

Reuters
·
Jan 08

BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA

Reuters
·
Jan 08

MoonLake Immunotherapeutics Shares Rise 35% Premarket After Meeting With US FDA Regarding Co's Skin Disease Drug Marketing Application

THOMSON REUTERS
·
Jan 08

MoonLake provides update following positive feedback from U.S. FDA for SLK

TIPRANKS
·
Jan 08

Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement

Stock Track
·
Jan 08

MoonLake Immunotherapeutics to Host Investor Day to Discuss FDA Feedback and Reveal New Clinical Data

Reuters
·
Jan 08

MoonLake Immunotherapeutics - Plans Bla Submission for Slk in Hs in H2 2026

THOMSON REUTERS
·
Jan 08

MoonLake Immunotherapeutics - FDA Confirms MoonLake Can Establish See Without Additional Trials

THOMSON REUTERS
·
Jan 08

MoonLake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA and Announces Investor Day

THOMSON REUTERS
·
Jan 08

MoonLake Immunotherapeutics Faces Securities Fraud Class Action

Reuters
·
Dec 15, 2025

MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations

Reuters
·
Dec 12, 2025

Moonlake Immunotherapeutics Chief Scientific Officer Kristian Reich Reports Sale of Common Shares

Reuters
·
Dec 11, 2025